• Five commercial agreements signed, expanding AlgoraeRx's portfolio
• TGA accepted two registration dossiers for evaluation
• AI drug-discovery pipeline scaled with over 478,000 synergy predictions
• Named healthcare and life sciences launch partner in Sovereign AI Infrastructure
• Strengthened commercial team with new Head of Sales

Algorae Pharmaceuticals Ltd (ASX: 1AI) reported significant progress in its commercial and AI drug-discovery operations for the quarter ended 30 June 2026. The company expanded its commercial platform with two new agreements, bringing the total to five agreements covering various therapeutic categories. AlgoraeRx, the company's commercial arm, also made progress in regulatory submissions, with two product registration dossiers accepted by the TGA for evaluation. On the research front, the company completed a multi-anchor drug combination program, generating over 478,000 synergy predictions. Additionally, Algorae was named the healthcare and life sciences launch partner in the Sovereign AI Infrastructure initiative. The company also appointed a new Head of Sales and secured a public hospital supply contract in New South Wales, marking a significant milestone in its commercial strategy.